Gadobutrol (Gadovist, BAY86-4875)

DRUG8 trials

Sponsors

Bayer

Conditions

Carotid StenosisEpidemiologic FactorsFibrosisMagnetic Resonance AngiographyMagnetic Resonance ImagingRenal Artery ObstructionRenal Impairment

Phase 3

Gadobutrol Magnevist-controlled Body Study

CompletedNCT01050829

BayerMagnetic Resonance Imaging

Start: 2010-01-31End: 2011-04-30Updated: 2014-12-30

Gadobutrol Enhanced MRA of the Renal Arteries

CompletedNCT01344460

BayerRenal Artery Obstruction

Start: 2011-05-31End: 2012-07-31Updated: 2015-08-26

Gadobutrol Enhanced MRA of the Supra-aortic Vessels

CompletedNCT01344447

BayerCarotid Stenosis

Start: 2011-05-12End: 2014-05-28Updated: 2019-01-04

Safety and Efficacy of Gadobutrol 1.0 Molar in Japanese Subjects for CNS Imaging

CompletedNCT01660841

BayerMagnetic Resonance Imaging

Start: 2012-09-30End: 2013-08-31Updated: 2014-10-01

Phase 4

Safety of Gadovist in Renally Impaired Patients

CompletedNCT00828737

BayerFibrosis, Renal Impairment

Start: 2008-12-31End: 2015-01-31Updated: 2016-02-18

Unknown Phase

Patient Characteristics in Daily Radiological Practice of Gadovist® Application (PATRON)

CompletedNCT00874640

BayerEpidemiologic Factors

Start: 2009-03-31End: 2011-11-30Updated: 2014-02-20

Observational Study on the Safety and Tolerability of Gadobutrol (Gadovist) Among Filipino Patients in Magnetic Resonance Imaging

CompletedNCT00905879

BayerMagnetic Resonance Imaging

Start: 2009-06-30End: 2011-01-31Updated: 2013-04-26

GARDIAN, Gadovist in Routine Diagnostic Magnetic Resonance Imaging Administration in Non-selected Patients

CompletedNCT01095081

BayerMagnetic Resonance Angiography, Magnetic Resonance Imaging

Start: 2010-07-31End: 2013-04-30Updated: 2015-01-21